GlassScriptPhysician profile
Prisca A Diala
NPI 1154516714
$4,717.20
in general payments reported to CMS, 2019-2025
24 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $139 · 2021: $1,095 · 2022: $549 · 2023: $865 · 2024: $830 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $1,227.11 | 2021-2022 | |
| Abbvie INC. | $707.43 | 2022-2025 | Durysta, Ozurdex |
| Regeneron Healthcare Solutions, INC. | $427.74 | 2022-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $417.35 | 2022-2025 | Syfovre |
| Amgen INC. | $237.71 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $226.16 | 2021-2023 | |
| Allergan, INC. | $219.13 | 2019-2021 | |
| Genentech USA, INC. | $203.58 | 2019-2025 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $176.54 | 2023-2025 | Cequa |
| Dompe US, INC. | $170.81 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $161.12 | 2023-2024 | Xipere, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $126.53 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $68.70 | 2024-2025 | Xdemvy |
| Alimera Sciences, INC. | $66.19 | 2023-2024 | Yutiq, Iluvien |
| Astellas Pharma US INC | $65.64 | 2023-2025 | Izervay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $34.73 | 2022 | |
| Ani Pharmaceuticals, INC. | $33.04 | 2025 | Iluvien |
| Oyster Point Pharma, INC. | $32.45 | 2022-2023 | Tyrvaya |
| Alcon Vision LLC | $29.35 | 2022 | |
| Ocular Therapeutix, INC. | $19.81 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Biogen, INC. | $17.29 | 2022 | |
| Harrow Eye, LLC | $16.61 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prisca Diala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.